ライフサイエンスコーパス: esophagitis

1 d acid-related disease (peptic ulcer, reflux esophagitis).

2 18 with achalasia, and 15 with eosinophilic esophagitis.

3 and IgG4 in the development of eosinophilic esophagitis.

4 associated with postoperative dysphagia and esophagitis.

5 butions in our understanding of eosinophilic esophagitis.

6 ophageal candidiasis, and 2 had eosinophilic esophagitis.

7 umnar epithelial metaplasia caused by reflux esophagitis.

8 a low prevalence of new-onset dysphagia and esophagitis.

9 of gastroesophageal reflux disease, such as esophagitis.

10 distinguished from noneosinophilic forms of esophagitis.

11 al-like columnar metaplasia linked to reflux esophagitis.

12 and patients with chronic (noneosinophilic) esophagitis.

13 n children and adolescents with eosinophilic esophagitis.

14 n children and adolescents with eosinophilic esophagitis.

15 bowel disease, small-bowel obstruction, and esophagitis.

16 role for periostin in allergic eosinophilic esophagitis.

17 ountered and well studied EGID, eosinophilic esophagitis.

18 of the clinical presentation of eosinophilic esophagitis.

19 the evaluation and treatment of eosinophilic esophagitis.

20 nonerosive reflux disease and 17 as erosive esophagitis.

21 n, diagnosis, and management of eosinophilic esophagitis.

22 d allergy in many patients with eosinophilic esophagitis.

23 racterize the underlying molecular events in esophagitis.

24 ionate (FP) in the treatment of eosinophilic esophagitis.

25 pediatric patients with active eosinophilic esophagitis.

26 nct from that associated with non-EE chronic esophagitis.

27 re may be indicative of underlying lichenoid esophagitis.

28 l but will miss subtle signs of eosinophilic esophagitis.

29 ageal stricture (grade 2) and 1 (2%) grade 4 esophagitis.

30 cally homes to the esophagus in eosinophilic esophagitis.

31 Four patients (28%) had esophagitis.

32 e responsible for reducing LES tone in human esophagitis.

33 gs were considered compatible with lichenoid esophagitis.

34 P = .001), and all patients had evidence of esophagitis.

35 sy specimens from patients with eosinophilic esophagitis.

36 ronic rhinosinusitis (CRS), and eosinophilic esophagitis.

37 1.2%, respectively; P < .001), and mucositis/esophagitis (18.6% v 14.4%, respectively; P = .0246).

38 nce: 0.19; 95% CI: -0.07 to 0.46; P = 0.15), esophagitis (19% vs 13%; RR: 1.42; 95% CI: 0.69-2.91; P

39 ation (16%), diarrhea (8%), dysphagia (10%), esophagitis (20%), fatigue (12%), hyperglycemia (6%), na

40 In total, 230 reflux esophagitis, 224 Barrett's esophagus, and 227 esophageal

41 3 to 4 pneumonitis (12% vs 9%; P = .12) and esophagitis (23% vs 21%; P = .27) were similar.

42 e Pneumocystis pneumonia (PCP, 28%), Candida esophagitis (23%), and Kaposi sarcoma (KS, 16%).

43 inority of patients had heartburn (24.3%) or esophagitis (27.4%), and these patients were successfull

44 The principal toxicity was esophagitis (29% grade 3 or 4 esophagitis, with one pati

45 oncurrent chemoradiotherapy included grade 3 esophagitis (7%) and grade 3/4 neutropenia (43%).

46 We evaluated MI in 61 patients with erosive esophagitis, 81 with nonerosive but pH-abnormal GERD, 93

47 Severe erosive esophagitis after a 2-month course of proton-pump inhibi

48 ory diseases, including asthma, eosinophilic esophagitis, allergic rhinitis, and atopic dermatitis.

49 control, 82% ceased PPI therapy, 100% healed esophagitis and 45% normalized EAE.

50 h normal pH metry, 2 were found with erosive esophagitis and 7 without endoscopic abnormalities.

51 ology, including 22% with moderate to severe esophagitis and 7% with Barrett's esophagus.

52 specimens from 11 subjects with eosinophilic esophagitis and 8 without (controls) were assessed for I

53 specimens from 24 subjects with eosinophilic esophagitis and 9 without (controls).

54 ld be considered high risk to develop reflux esophagitis and advised of the management considerations

55 MI was measured at the site of esophagitis and at 2, 5, and 10 cm above the squamocolum

56 e esophageal epithelium (EE), such as reflux esophagitis and cancer, are rising in incidence.

57 of immune cell-mediated esophageal injury in esophagitis and confirms the utility of the OTC platform

58 derstand the pathophysiology of eosinophilic esophagitis and development of novel therapies.

59 sessable patients, 17 (25%) had grade 3 to 4 esophagitis and eight (12%) had grade 3 febrile neutrope

60 , SSc patients may be complicated by erosive esophagitis and eventually by Barrett's esophagus and es

61 collected from 15 subjects with eosinophilic esophagitis and from 41 without (controls), and assayed

62 is a significant risk factor, such as reflux esophagitis and gallstones.

63 IKKbetaca mice developed esophagitis and had increased numbers of blood vessels i

64 No such difference was observed between mid-esophagitis and healthy controls.

65 psies are obtained in the setting of erosive esophagitis and if pathology findings suggest LGD, or if

66 egan, the groups with histologic evidence of esophagitis and normal histologies did not differ in sev

67 siveness, as well as eosinophilic gastritis; esophagitis and other organ damage occurred in some case

68 as an association of H. pylori genotype with esophagitis and PUD.

69 opose a link between both healing of erosive esophagitis and the slower remission of upper and lower

70 32 (G allele protective against eosinophilic esophagitis) and rs2416257 (A allele associated with low

71 % grade 4 hematologic toxicities, 8% grade 3 esophagitis, and 7% grade 3 to 4 pneumonitis.

72 , GBP reduces GERD symptoms, improves reflux esophagitis, and decreases esophageal acid exposure for

73 any diseases, including asthma, eosinophilic esophagitis, and eczema.

74 rease in the risk for GERD symptoms, erosive esophagitis, and esophageal adenocarcinoma.

75 practice: vitamin D deficiency, eosinophilic esophagitis, and health literacy.

76 Vitamin D deficiency, eosinophilic esophagitis, and poor health literacy are three importan

77 intestinal symptoms overlapping with erosive esophagitis, and provides sustained improvement in HRQoL

78 after LNF, and esophageal acid exposure and esophagitis are similar, with no differences in heartbur

79 e in the literature surrounding eosinophilic esophagitis as more than two-thirds of the articles writ

80 se with unique features that include chronic esophagitis, atopy, immune sensitization to oral antigen

81 between the use of NSAIDs and risk of reflux esophagitis, Barrett's esophagus, and esophageal adenoca

82 ty: gastroesophageal reflux disease, erosive esophagitis, Barrett's esophagus, esophageal adenocarcin

83 henocopies human pathology with evolution of esophagitis, Barrett-like metaplasia and EAC.

84 complexes were found in 2 of 5 eosinophilic esophagitis biopsy specimens based on ultrastructural an

85 properly identify patients with eosinophilic esophagitis but also be informed about the current treat

86 ens from 21 of 24 patients with eosinophilic esophagitis, but in none of the specimens from 9 control

87 Lichenoid esophagitis causing death has not been reported previous

88 only slightly in patients with eosinophilic esophagitis, compared with controls.

89 er in the group with histologic evidence for esophagitis, compared with patients who had normal histo

90 my samples from 2 patients with eosinophilic esophagitis contained 180 and 300 IgG4 plasma cells/maxi

91 0 controls, stored in the Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, were analyzed.

92 hallenged the traditional notion that reflux esophagitis develops when esophageal surface epithelial

93 and sex-matched subjects with mid-esophagus esophagitis (diseased-control), and histologically norma

94 is in head and neck cancer, or prevention of esophagitis during concurrent chemoradiotherapy for non-

95 Most reports on eosinophilic esophagitis (EE) are limited to small series from single

96 Eosinophilic esophagitis (EE) is an emerging disease associated with

97 Eosinophilic esophagitis (EE) is an emerging disorder with a poorly u

98 Eosinophilic esophagitis (EE) is an increasingly recognized disease t

99 oposed that the pathogenesis of eosinophilic esophagitis (EE) is mediated by an IL-13-driven epitheli

100 ents had a "new" disease termed eosinophilic esophagitis (EE).

101 Eosinophilic esophagitis (EoE) afflicts both children and adults.

102 dose reduction in patients with eosinophilic esophagitis (EoE) and analyzed esophageal transcriptomes

103 An association between eosinophilic esophagitis (EoE) and celiac disease (CD) has been sugge

104 cur frequently in patients with eosinophilic esophagitis (EoE) and harbor a risk for severe esophagea

105 epresenting 2 entities known as eosinophilic esophagitis (EoE) and PPI-responsive esophageal eosinoph

106 eeded to assess the activity of eosinophilic esophagitis (EoE) and to provide end points for clinical

107 ue from individuals with active eosinophilic esophagitis (EoE) and were present at markedly higher le

108 Eosinophilic esophagitis (EoE) exhibits esophageal dysfunction owing

109 n (IL)-5 in the pathogenesis of eosinophilic esophagitis (EoE) has been established in animal models;

110 Eosinophilic esophagitis (EoE) has emerged over the past 2 decades as

111 d translation, in patients with eosinophilic esophagitis (EoE) has not been explored.

112 inks between food allergens and eosinophilic esophagitis (EoE) have been established, but the interpl

113 elial fibrosis in subjects with eosinophilic esophagitis (EoE) have not been delineated.

114 Eosinophilic esophagitis (EoE) is a chronic allergic disease with lim

115 Eosinophilic esophagitis (EoE) is a chronic antigen-driven allergic i

116 Eosinophilic esophagitis (EoE) is a chronic antigen-mediated clinicop

117 Eosinophilic esophagitis (EoE) is a chronic antigen-mediated disease

118 Eosinophilic esophagitis (EoE) is a chronic disease characterized cli

119 Eosinophilic esophagitis (EoE) is a chronic immune/antigen-mediated c

120 Eosinophilic esophagitis (EoE) is a chronic inflammatory disease with

121 Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder ass

122 Eosinophilic esophagitis (EoE) is a chronic TH2 inflammatory disease

123 Eosinophilic esophagitis (EoE) is a chronic, immune/antigen-mediated

124 Eosinophilic esophagitis (EoE) is a chronic, inflammatory disease of

125 Eosinophilic esophagitis (EoE) is a chronic, Th2-type inflammatory di

126 Eosinophilic esophagitis (EoE) is a clinicopathologic entity of incre

127 Eosinophilic esophagitis (EoE) is a condition characterized by dense

128 Eosinophilic esophagitis (EoE) is a food allergy-associated inflammat

129 Eosinophilic esophagitis (EoE) is a new disease.

130 Like many rare diseases, eosinophilic esophagitis (EoE) is a poorly understood disorder, and a

131 Eosinophilic esophagitis (EoE) is a rapidly emerging, chronic inflamm

132 Eosinophilic esophagitis (EoE) is a recently recognized inflammatory

133 Eosinophilic esophagitis (EoE) is a severe inflammatory disease of th

134 Eosinophilic esophagitis (EoE) is a Th2 cytokine-associated disease c

135 Eosinophilic esophagitis (EoE) is an allergic disease of increasing w

136 Eosinophilic esophagitis (EoE) is an allergic disorder characterized

137 Eosinophilic esophagitis (EoE) is an allergic disorder characterized

138 Eosinophilic esophagitis (EoE) is an atopic disease characterized by

139 Eosinophilic esophagitis (EoE) is an emerging chronic inflammatory di

140 Eosinophilic esophagitis (EoE) is an emerging tissue-specific allergi

141 Eosinophilic esophagitis (EoE) is an esophageal disorder predominantl

142 Eosinophilic esophagitis (EoE) is an esophageal inflammatory disease

143 Eosinophilic esophagitis (EoE) is an inflammatory disorder of the eso

144 Although eosinophilic esophagitis (EoE) is associated with certain gene varian

145 Eosinophilic esophagitis (EoE) is caused by immunologic reactions to

146 IMS: Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label use of cortico

147 Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label use of cortico

148 Eosinophilic esophagitis (EoE) is of increasing prevalence and believ

149 Eosinophilic esophagitis (EoE) is often associated with atopic airway

150 logic and molecular features of eosinophilic esophagitis (EoE) is unclear.

151 e observed an increased risk of eosinophilic esophagitis (EoE) mostly among first-degree relatives, s

152 Eosinophilic esophagitis (EoE) now represents a commonly recognized d

153 Patients with eosinophilic esophagitis (EoE) often become dysphagic from the combin

154 h the increasing recognition of eosinophilic esophagitis (EoE) over the past two decades, pharmacolog

155 Diagnostic evaluation of eosinophilic esophagitis (EoE) remains difficult, particularly the as

156 agnosis and/or recrudescence of eosinophilic esophagitis (EoE) remains unclear, with some studies dem

157 y to trigger allergies achieves eosinophilic esophagitis (EoE) remission in children, data on its pro

158 BACKGROUND & AIMS: Adults with eosinophilic esophagitis (EoE) typically present with dysphagia and f

159 properties of the esophagus in eosinophilic esophagitis (EoE) using the functional luminal imaging p

160 Eosinophilic esophagitis (EoE) was historically distinguished from ga

161 Eosinophilic esophagitis (EoE) was recognized as its own entity in th

162 ological findings suggestive of eosinophilic esophagitis (EoE) who achieve complete remission on PPI

163 ic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory disorder trigg

164 Eosinophilic esophagitis (EoE), a food antigen-mediated disease, is e

165 the esophagus of patients with eosinophilic esophagitis (EoE), a recently recognized allergic disord

166 ecular and cellular etiology of eosinophilic esophagitis (EoE), an emerging tissue-specific allergic

167 id increase in the incidence of eosinophilic esophagitis (EoE), but potential exposures have not been

168 In patients with eosinophilic esophagitis (EoE), eosinophils accumulate and release gr

169 hological conditions, including eosinophilic esophagitis (EoE), in which basal progenitor cells becom

170 pic, and histologic features of eosinophilic esophagitis (EoE), review the current diagnostic guideli

171 n emerging form of esophagitis, eosinophilic esophagitis (EoE), which is currently diagnosed by histo

172 een used to treat patients with eosinophilic esophagitis (EoE), yielding varied results.

173 mination diets in patients with eosinophilic esophagitis (EoE).

174 from the diets of patients with eosinophilic esophagitis (EoE).

175 pic procedures in patients with eosinophilic esophagitis (EoE).

176 geal reflux disease (GERD), and eosinophilic esophagitis (EoE).

177 major concern for patients with eosinophilic esophagitis (EoE).

178 pria is a known complication of eosinophilic esophagitis (EoE).

179 l corticosteroid treatments for eosinophilic esophagitis (EoE).

180 QOL) of pediatric patients with Eosinophilic Esophagitis (EoE).

181 timate the biologic activity of eosinophilic esophagitis (EoE).

182 pproach for diagnosis of an emerging form of esophagitis, eosinophilic esophagitis (EoE), which is cu

183 tercellular space width, endoscopic grade of esophagitis, esophageal acid exposure, and mucosal imped

184 n symptoms of GERD and those of eosinophilic esophagitis, functional dyspepsia, and gastroparesis, po

185 Esophagitis further healed in 75% (6/8) of patients.

186 icemia, nutritional and metabolic disorders, esophagitis, gastroenteritis, and digestive disorders we

187 controlled trial of adults with eosinophilic esophagitis given an antibody against IgE (omalizumab, n

188 erence in severity of in-field toxicities of esophagitis (grade 3 and 4 were, respectively, 30% and 2

189 AM did not significantly reduce esophagitis >/= grade 3 in patients receiving hyperfract

190 was defined by abnormal pH-testing or reflux esophagitis >Los Angeles grade A.

191 geal tissues from patients with eosinophilic esophagitis had a 45-fold increase in IgG4 compared with

192 Subjects with eosinophilic esophagitis had increased serum levels of IgG4 that reac

193 provide further elimination of symptoms and esophagitis healing.

194 mary outcomes were esophageal acid exposure, esophagitis, heartburn score, dilatation for dysphagia,

195 hed patients with EoE from those with reflux esophagitis, identified by pH-impedance testing.

196 to as the EDP) that identifies patients with esophagitis in a fast, objective, and mechanistic manner

197 stologic events in the development of reflux esophagitis in a rat model and performed in vitro experi

198 thophysiology, and treatment of eosinophilic esophagitis in both children and adults.

199 The etiology of eosinophilic esophagitis in children is reported to be associated wit

200 ons of anti-TNF prevented the development of esophagitis in IKKbetaca mice.

201 te cupping of reflux symptoms and healing of esophagitis in patients with GERD.

202 ber of publications relating to eosinophilic esophagitis in terms of case reports, cohorts of patient

203 e a case, diagnosed by autopsy, of lichenoid esophagitis in which massive bleeding from generalized e

204 native concept for the development of reflux esophagitis in which refluxed gastric juice does not dir

205 ents (drug inefficacy, gastritis, and reflux esophagitis) in two patients were considered related to

206 commonly involved foods causing eosinophilic esophagitis include milk, eggs, nuts, beef, wheat, fish,

207 be useful for obvious signs of eosinophilic esophagitis including rings and strictures.

208 The pathogenesis of eosinophilic esophagitis involves environmental and genetic factors,

209 Eosinophilic esophagitis is a chronic allergic disease with insuffici

210 Eosinophilic esophagitis is a chronic, immune-mediated inflammatory d

211 Eosinophilic esophagitis is a clinicopathologic disease of increasing

212 Therefore, eosinophilic esophagitis is a disease with unique features that inclu

213 Eosinophilic esophagitis is a disorder increasing in frequency that t

214 Esophagitis is a known adverse effect of bisphosphonate

215 Eosinophilic esophagitis is a new disease commonly confused with gast

216 Eosinophilic esophagitis is a recently recognized but expanding disor

217 Eosinophilic esophagitis is an allergy-based disorder.

218 Lichenoid esophagitis is an appropriate diagnostic term when clini

219 Eosinophilic esophagitis is an emerging disease that is distinguished

220 Eosinophilic esophagitis is an increasingly recognized disorder with

221 Eosinophilic esophagitis is an increasingly recognized problem.

222 Eosinophilic esophagitis is an isolated, eosinophilic inflammation of

223 Eosinophilic esophagitis is being diagnosed in both children and adul

224 Reflux esophagitis is believed to be caused by the caustic effe

225 By contrast, eosinophilic esophagitis is characterized by low levels of IgE specif

226 le of specific foods in causing eosinophilic esophagitis is elucidated by several studies, and microR

227 oods, indicate that, in adults, eosinophilic esophagitis is IgG4-associated, and not an IgE-induced a

228 rent treatments, recognition of eosinophilic esophagitis is important.

229 Diagnosis of eosinophilic esophagitis is suggested by food impaction in a young ad

230 Although eosinophilic esophagitis is treatable, it is thought to be a chronic

231 Eosinophilic esophagitis is usually triggered by foods, by unclear me

232 "Lichenoid esophagitis" is a descriptive term for a lichenoid patte

233 Eosinophilic esophagitis-like esophageal inflammation was induced in

234 the presence of active inflammation (erosive esophagitis, Los Angeles grade C and D).

235 rt the role of the allergist in eosinophilic esophagitis management, especially for food allergen tes

236 ortant for successful long-term eosinophilic esophagitis management.

237 Eosinophilic esophagitis may affect individuals at any age, although

238 ings suggest that the pathogenesis of reflux esophagitis may be cytokine-mediated rather than the res

239 lustrated here for the first time, lichenoid esophagitis may cause ulceration and mucosal sloughing s

240 The association of minimal change esophagitis (MCE) with GERD is controversial.

241 ic chemical injuries develop rapidly whereas esophagitis might not appear until weeks after the induc

242 t development phase, the PedsQL Eosinophilic Esophagitis Module is now undergoing multisite national

243 tent validity of the new PedsQL Eosinophilic Esophagitis Module items was supported in the current in

244 lity of Life Inventory (PedsQL) Eosinophilic Esophagitis Module.

245 complications included: cellulitis (n = 1), esophagitis (n = 1), aspiration pneumonia (n = 1), and t

246 to groups with histologic evidence of reflux esophagitis (n = 50), or normal histology results (n = 5

247 rformed a prospective study of patients with esophagitis (n = 8) or Barrett's esophagus (n = 6); medi

248 astric/duodenal ulcer (n=2), and hemorrhagic esophagitis (n=1).

249 Secondary outcomes included healing of esophagitis, normalization of EAE and PPI use after TF.

250 icroaerophiles and primarily correlated with esophagitis (odds ratio, 15.4) and Barrett's esophagus (

251 In a prospective study of patients with esophagitis or Barrett's esophagus, we found belt compre

252 zumab did not alter symptoms of eosinophilic esophagitis or eosinophil counts in biopsy samples compa

253 cantly lower in patients with GERD (erosive esophagitis or nonerosive but pH-abnormal GERD) or eosin

254 d biopsy, those with histologic evidence for esophagitis or normal histology findings are at increase

255 and acid-related complications (ie, erosive esophagitis or peptic stricture) should take a PPI for s

256 umab did not reduce symptoms of eosinophilic esophagitis or tissue eosinophil counts compared with pl

257 types were histologically defined as normal, esophagitis, or Barrett's esophagus (intestinal metaplas

258 2m2) was associated with a decreased risk of esophagitis (P = 0.003 and 0.0003, respectively).

259 E at endoscopy (P < 0.001), and histological esophagitis (P = 0.02).

260 interleukin-9 are important in eosinophilic esophagitis pathogenesis.

261 ta production and signaling, to eosinophilic esophagitis pathophysiology.

262 Esophagitis patients were recruited from Northern Irelan

263 Eosinophilic esophagitis patients were stratified based on the diagno

264 s without GERD or patients with eosinophilic esophagitis; patients with GERD had low MI closer to the

265 The primary toxicities included esophagitis, pulmonary, and fatigue.

266 RD cases, we identified patients with reflux esophagitis (RE).

267 ctic sensitivity to peanut, (2) eosinophilic esophagitis related to cow's milk, and (3) delayed anaph

268 , quality of life, esophageal acid exposure, esophagitis, resting lower esophageal sphincter pressure

269 Esophagitis reversal was observed in 92% patients in gro

270 Studies on eosinophilic esophagitis show a relationship to connective tissue dis

271 que epidemiologic parameters of eosinophilic esophagitis, some of its natural history, and its increa

272 pathogenesis, and treatment of eosinophilic esophagitis, some of which will be summarized here.

273 Reflux esophagitis started at postoperative day 3 with lymphocy

274 last 5 years, the emergence of eosinophilic esophagitis stimulated many case series; the new frontie

275 nary study of 12 patients with severe reflux esophagitis successfully treated with PPI therapy, stopp

276 terans Affairs Medical Center who had reflux esophagitis successfully treated with proton pump inhibi

277 s, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and systemic imm

278 The Pediatric Eosinophilic Esophagitis Symptom Score (PEESS v2.0) measures patient-

279 rosive but pH-abnormal GERD) or eosinophilic esophagitis than in patients without GERD or patients wi

280 ized that this platform can be used to model esophagitis to better understand the interactions betwee

281 ality of life (HRQoL) with healing of reflux esophagitis to further derive insights into the underlyi

282 anscriptome overlapped with the eosinophilic esophagitis transcriptome.

283 tome markedly distinct from the eosinophilic esophagitis transcriptome.

284 5 % of the on-demand group developed reflux esophagitis versus none in the continuous group (P < 0.0

285 The rate of >/= grade 3 esophagitis was 30% with AM versus 34% without AM (P = .

286 Reflux esophagitis was detected in 24 (45%), 17 (32%), and 10 p

287 Esophagitis was found at endoscopy in 34% and confirmed

288 At long-term follow-up, esophagitis was found in 14 group A (30%) and in 18 grou

289 oscopic and histological characterization of esophagitis was performed according to the Los Angeles a

290 Reflux esophagitis was seen in 17 cases (32.7%) of SSc and only

291 Rates of grade 2 and 3 acute esophagitis were 18 (28%) and 5 (8%), respectively.

292 626 patients with reflux esophagitis were enrolled into one of two treatment grou

293 h eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses.

294 Esophagitis, whether caused by acid reflux, allergic res

295 corticoid-treated patients with eosinophilic esophagitis who had 2 consecutive endoscopic biopsy spec

296 al tissues from 2 patients with eosinophilic esophagitis who underwent esophagectomy and 47 consecuti

297 rs the role of the allergist in eosinophilic esophagitis with a focus on the literature from the past

298 MI patterns identified patients with esophagitis with higher levels of specificity (95%) and

299 nducing histologic remission in eosinophilic esophagitis, with a more pronounced effect in nonallergi

300 l toxicity was esophagitis (29% grade 3 or 4 esophagitis, with one patient with grade 3 tracheoesopha